What actually changes for your pharmacy on 27 November 2026

On 6 August 2026 FDA granted small business dispensers a further one-year exemption, running from 27 November 2026 until 27 November 2027. So the honest answer to the question in this page’s title is: less than it did a week ago. Two things still happen on 27 November 2026. The first exemption ends and the second begins. And FDA takes the 25-employee headcount that decides who holds the second one on that day, footnote 14 of the new letter reads “The total number of employees as of November 27, 2026.” It is now the day your eligibility is measured rather than the day the requirements land.

FDA gave its reason in the letter: “there are still steps under section 582(g)(3) of the FD&C Act that are not yet completed as the current small business dispensers’ compliance date of November 27, 2026 approaches.” Those steps are the Assessment of Small Dispensers, an independent study of whether package-level interoperable tracing is feasible for pharmacies your size, a public comment period on the finished assessment, and a public meeting about it. The extension exists to make room for that process, and FDA is separately encouraging small dispensers to complete the assessment survey by 22 September 2026.

“The exemption expires 27 November 2027” is true and almost useless on its own. It does not tell you what lands on you that day, and it does not distinguish between the parts your wholesaler already handles and the parts nobody is handling.

The exemption is written against a specific list: the requirements of §582(g)(1) of the Federal Food, Drug and Cosmetic Act, lettered (A) through (F). The FDA sets them out one by one in the same document that grants the relief. Read as six obligations rather than one deadline, the shape of the work changes.

The six, in the FDA’s own terms

Quoted from the exemptions document, condensed only where the statutory cross-references run long:

• (A) Electronic, interoperable exchange. That transaction information and transaction statements “be exchanged in a secure, interoperable, electronic manner” under the standards in the §582(h) guidances. This is the EPCIS-shaped part.
• (B) Package-level product identifier. That the transaction information required to be exchanged “include the product identifier at the package level for each package included in the transaction.” Until the date, small business dispensers and their trading partners “may continue to exchange transaction information that does not include the product identifier at the package level.”
• (C) Package-level verification. Systems and processes for verification of product at the package level, including the standardized numerical identifier, in accordance with the §582 guidances.
• (D) Prompt response to an official request. Systems and processes “necessary to promptly respond with the transaction information and transaction statement for a product upon a request by the Secretary, or other appropriate Federal or State official, in the event of a recall or for the purposes of investigating a suspect product or an illegitimate product.”
• (E) Gathering information back to the manufacturer. Systems and processes to promptly facilitate gathering the transaction information for each transaction going back to the manufacturer, on an official request, or on a request from an authorised trading partner made securely.
• (F) Saleable returns. That anyone accepting a saleable return have systems and processes in place to accept it, and accept it “only if such person can associate the saleable return product with the transaction information and transaction statement for the product.”

Which of these is actually your problem

(A), (B) and (C) are data obligations that move with the product. For an independent pharmacy buying from a primary wholesaler, the serialized data is generated upstream and delivered into a portal or a feed you already have. The work there is confirming the connection exists and that someone knows where the data lands, not building a tracing platform.

(D) and (E) are the ones that catch people, because they are not about data at all. They are about systems and processes, whether a request arriving on a Tuesday reaches a named person, who pulls what, and how fast. A pharmacy can hold every byte of required data and still fail (D) because no one has ever written down who answers. The 6 August 2026 letter changed who the relief on these two is addressed to, and it is worth reading closely: on (D) it now covers “Small business dispensers and their trading partners” jointly, and on (E) the qualifier moved onto you, “If small business dispensers directly transacted the product(s) subject to the request, they may use current methods to respond.” Product that reached you through a supplier you did not transact with directly sits outside that sentence.

(F) is narrow and often mis-scoped. It bites on returns you accept back into saleable inventory, which for most independents is a thin flow, but the obligation is to be able to associate the return with its transaction information, which is a procedure, not a purchase.

Two things people get wrong about the date

If you have 26 or more full-time pharmacists and technicians, this is not your date. The relief FDA granted to larger dispensers ran “from November 27, 2024, until November 27, 2025.” That window closed eight months ago. There is no automatic grant carrying a 26+ FTE dispenser to 2026, and individually granted waivers carry their own end dates. Count across the whole corporate entity before assuming which of the two dates applies to you, this is the single most common misreading, and we have written it up in full.

Do not rebuild transaction history. The FDA notes in the same document that “Beginning on November 27, 2023, section 582(k)(1) of the FD&C Act effectively ended the requirement for trading partners to provide and receive transaction history.” It is worth saying because older compliance checklists still list three documents, TI, TH and TS. Preparing for the sunset by reconstructing a requirement that was retired is wasted work.

What to have ready before the date

None of (D), (E) or (F) is satisfied by an intention. Each is satisfied by a dated, findable written procedure that an inspector can read and a member of staff can follow. Concretely:

• A dated determination of which exemption track you are on, with the entity-wide count behind it.
• A trading-partner verification log, who you buy from, and how you established they are authorised.
• A tracing response runbook naming the person, the source system and the turnaround.
• Suspect and illegitimate product SOPs, including quarantine and FDA notification.
• A saleable-returns procedure that ties a return to its transaction information.
• Training attestation and a retention plan covering the six-year requirement.

Where DoseTrace fits

DoseTrace does not move serialized data and is not an EPCIS platform, (A), (B) and (C) stay with your wholesaler and your existing systems. It produces the nine-document binder that covers the written half, from a 15-minute intake, flat fee $99, one time, no subscription.

Check which exemption track you are on, free, it takes about a minute and stores nothing. Contact reaches a person.

If you are being sold a platform for (A), (B) and (C) and are not sure whether it also covers (D), (E) and (F), that boundary is the whole of DSCSA software or a readiness binder.

If your answer to all six is “my wholesaler does that”, the letter is narrower than that answer assumes: it exempts you and your trading partners jointly, and it hands only (F), saleable returns, to the partner alone. Which duties actually move and which three stay with you regardless is what your pharmacy still owes when your wholesaler handles DSCSA.

And if the answer is that someone else should write all six up for you, there are six kinds of organisation that will , who can prepare DSCSA documentation for your pharmacy names each one.

The six obligations, the 27 November 2027 date, the 27 November 2026 headcount date and the transaction-history footnote are quoted from the FDA document that granted this exemption , DSCSA Exemptions from Certain Requirements Under Section 582 of the FD&C Act for Small Business Dispensers Until November 27, 2027, issued 6 August 2026, which supersedes the 12 July 2024 letter this page previously quoted. FDA republished it at the same address, so that URL no longer returns the 2024 text. The 26-or-more-FTE window is quoted from the separate letter DSCSA Exemptions from Section 582(g)(1) and Other Requirements of the FD&C Act for Certain Trading Partners, issued 9 October 2024, which governs larger dispensers and does not grant the small-business exemption and is unaffected by the extension. Both retrieved and verified 11 August 2026. DoseTrace is not a law firm and nothing here is legal advice.